Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Clinical trial NCT01631552 · COMPLETED

Trial details

NCT number: NCT01631552
Sponsor: Gilead Sciences
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Gastric Adenocarcinoma Esophageal Cancer Hepatocellular Carcinoma Non-small Cell Lung Cancer Small Cell Lung Cancer Ovarian Epithelial Cancer Carcinoma Breast Stage IV Hormone-refractory Prostate Cancer Head and Neck Cancers- Squamous Cell Renal Cell Cancer Urinary Bladder Neoplasms Cervical Cancer

Start date: 2012-12-17
Primary completion: 2019-03-01
Enrollment: 515

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.